Incyte Corporation
INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor tā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$118.43
Price-0.91%
-$1.09
1Y
Price
Market Cap
$24.005b
Large
Price/Earnings 3y Avg5y Avg
15.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+44.9%
EBITDA Margin+35.0%
Net Profit Margin+29.6%
Free Cash Flow Margin+44.9%
EBITDA Margin+35.0%
Net Profit Margin+29.6%
Free Cash Flow MarginRevenue
$5.820b
+13.2%
1y CAGR+16.4%
3y CAGR+14.5%
5y CAGREarnings
$1.612b
+25.3%
1y CAGR+1258.6%
3y CAGR+962.8%
5y CAGREPS
$7.85
+22.5%
1y CAGR+1367.2%
3y CAGR+1044.0%
5y CAGRBook Value
$6.344b
$7.873b
Assets$1.528b
Liabilities$32.679m
DebtDebt to Assets
0.4%
-
Debt to EBITDAFree Cash Flow
$1.920b
+41.8%
1y CAGR+147.0%
3y CAGR+97.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company